trial

A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia

NCTId NCT00650793
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 473 (actual)
Sponsored by Johnson & Johnson
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
473 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2004-03
Primary completion
—
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Paliperidone

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
473
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
Paliperidone
drug
lead_sponsor
Johnson & Johnson
company
indication
Schizophrenia
indication
Schizophrenia
indication